The significance of two different free light chain immunoassays for monitoring of disease activity in multiple myeloma patients

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

MAISNAR Vladimír VÁVROVÁ J. MACHÁLKOVÁ K. TICHÝ M. RADOCHA J. FRIEDECKÝ B. HÁJEK Roman PALIČKA V. MALÝ J.

Year of publication 2010
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description For most patients with a monoclonal immunoglobulin, measuring FLC is unlikely to have additional benefit for monitoring of disease activity with the notable exception of those with nonsecretory/oligosecretory myeloma. FLCs monitoring could identify patients with resistance to current therapy regimens more quickly than M-Ig determination. Conversely the most rapidly responding patients may have a worse outcome. FLCs measurement can help us also in patients with early relapse still on chemotherapy or in case of free light chains escape phenomenon. Because of the kappa/lambda FLC ratio calculation is strongly influenced by measurement errors, therefore we recommend the preferential use of relevant FLC concentration values.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.